ARCA biopharma, Inc. (ABIO): Price and Financial Metrics

ARCA biopharma, Inc. (ABIO): $3.34

0.06 (+1.83%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add ABIO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#297 of 356

in industry

ABIO Price/Volume Stats

Current price $3.34 52-week high $4.49
Prev. close $3.28 52-week low $1.56
Day low $3.23 Volume 32,100
Day high $3.42 Avg. volume 825,527
50-day MA $3.36 Dividend yield N/A
200-day MA $2.20 Market Cap 48.45M

ABIO Stock Price Chart Interactive Chart >


ARCA biopharma, Inc. (ABIO) Company Bio


ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.


ABIO Latest News Stream


Event/Time News Detail
Loading, please wait...

ABIO Latest Social Stream


Loading social stream, please wait...

View Full ABIO Social Stream

Latest ABIO News From Around the Web

Below are the latest news stories about ARCA BIOPHARMA INC that investors may wish to consider to help them evaluate ABIO as an investment opportunity.

ARCA biopharma Announces Third Quarter 2023 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Oct. 18, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Dir

Yahoo | October 18, 2023

ARCA biopharma Announces Second Quarter 2023 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., July 21, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Di

Yahoo | July 21, 2023

We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | July 13, 2023

ARCA biopharma Announces First Quarter 2023 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., April 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Dir

Yahoo | April 24, 2023

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2022 financial results and provided a corporate update. In May 2022, the Company retained Ladenburg Th

Yahoo | February 24, 2023

Read More 'ABIO' Stories Here

ABIO Price Returns

1-mo -1.76%
3-mo 96.47%
6-mo 90.86%
1-year 59.05%
3-year -9.24%
5-year -48.54%
YTD 96.47%
2023 -28.27%
2022 10.23%
2021 -46.38%
2020 -29.78%
2019 -3.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!